The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
Texas MPN Workshop 2021 | Potential approval of pacritinib for the treatment of myelofibrosis
Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, discusses the rolling submission of a New Drug Application for the tyrosine kinase inhibitor pacritinib and outlines the impacts this potential approval could have on the treatment of patients with myelofibrosis. Dr Gerds talks on the Phase III PERSIST-2 (NCT02055781) trial which has demonstrated that pacritinib can be delivered safely in thrombocytopenic patients, a patient subgroup whose clinical needs have not been adequately served by ruxolitinib or other currently available agents. This interview took place at the Texas MPN Workshop: Second Annual Workshop and Meeting in 2021.
